May 7th 2024
If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
For Advanced Heme Malignancies, CAR T Cells Overcome Exhaustion, Tumor Escape
December 28th 2019Progress in the development of chimeric antigen receptor T-cell therapy and other cell-based therapies has led to new therapeutic options for advanced malignancies. CAR T-cell agents approved by the FDA in recent years include axicabtagene ciloleucel for diffuse large B-cell lymphoma and tisagenlecleucel for both DLBCL and acute lymphoblastic leukemia.
Read More
Immunotherapy Advances Are Explored in Merkel Cell Carcinoma
December 28th 2019Early-stage skin cancers that remain localized are often successfully treated through a variety of surgical techniques as well as radiation therapy, photodynamic therapy, and topical chemotherapy, but advanced cases that are beyond surgery may respond to immunotherapies. This setting will be discussed during the Society for Immunotherapy of Cancer’s 34th Annual Meeting.
Read More
Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations
December 27th 2019The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.
Watch
BLA Submitted for Liso-Cel Therapy in Patients With Large B-cell Lymphoma
December 19th 2019A Biologic License Application has been submitted for isocabtagene maraleucel, a chimeric antigen receptor T-cell agent, as a treatment for adult patients with relapsed or refractory large B-cell lymphoma after a minimum of 2 prior therapies, Bristol-Myers Squibb, the manufacturer, reported in a press release.
Read More
CARTITUDE-1 Trial Reports 100% Response Rate in Heavily Pretreated Myeloma
December 8th 2019Data from the phase Ib/II CARTITUDE-1 trial that were presented at the 2019 ASH Annual Meeting demonstrated the anti-BCMA CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with responses in 29 patients with heavily pretreated relapsed/refractory multiple myeloma.<br />
Read More
FDA Grants IND Clearance to CAR T-cell Drug ICTCAR014 for R/R Non-Hodgkin Lymphoma
December 5th 2019An Investigational New Drug application for chimeric antigen receptor-T cell agent, ICTCAR014, has been cleared by the FDA for treatment of patients with relapsed/refractory non-Hodgkin lymphoma, including those with PD-L1-positive tumors, according to a press release from Innovative Cellular Therapeutics.
Read More
Shifting the Focus to Newer Technologies for Immunotherapy Response
December 3rd 2019It is clear that cancer immunotherapy has progressed dramatically over the past 10 years, with over 20 FDA approvals for immune checkpoint receptor inhibitors targeting PD-1 and CTLA-4. However, we are still awaiting the next major advance in these inhibitory receptor targets that yields clinical benefit. In the meantime, additional advances have appeared.
Read More
Understanding Virus-Induced Cancers Can Elucidate Precancerous Lesion Development
November 28th 2019Approximately 20% of cancers worldwide are linked to an infectious agent. Currently, there are seven known oncogenic viruses, which include Epstein-Barr virus, hepatitis virus B and C, human papillomavirus, human T cell lymphoma virus 1, Kaposi sarcoma virus and Merkel cell polyomavirus. Among these agents, HBV, HCV and HPV each contribute to ap- proximately 5% of all cancer cases.
Read More
Applying CAR T Cells to the Treatment of Renal Cell Carcinoma
November 26th 2019In an interview with Targeted Oncology during the 2019 Kidney Cancer Research Summit, Wayne A. Marasco, MD, PhD, discussed the intricacy of engineering CAR T cells and the early data he has observed with the approach in RCC.
Read More
CAR T-Cell Therapy Impacts Role of Stem Cell Transplant in B-Cell ALL
November 22nd 2019In an interview with Targeted Oncology, Partow Kebriaei, MD, discussed the role of transplantation in patients with ALL following treatment with targeted cellular therapies, such as CAR T-cell therapy. She highlights the patient population that receives the most benefit from the use of CAR T-cell therapy and when transplant should be considered for these patients.
Read More
Immune-Regulating Mechanisms, New Combinations Explored as Immunotherapy Continues to Grow
November 22nd 2019Over the last decade, immunotherapeutic options have led to impressive clinical responses in patients with various cancer types and this has increased expectations for successful treatment of the disease. Despite immunotherapy results leading to clinical trials in melanoma, renal cell carcinoma and non–small cell lung cancer, the percentage of patients who respond to immunotherapy remains low; this highlights the need to identify the patient population that will best respond to these approaches.
Read More
Building upon the initial successes of anti–PD-1 and anti–CTLA-4 therapies has been a major focus of drug development over the past several years—basically, in search of other agents that could generate “immune-synergy.” What the term means and implies is critically important: It refers to drugs that work better together than alone (or in sequence) through their individual mechanisms of action to enhance the host immune-response to cancer.
Read More
Managing Neurotoxicity and Cytokine Release Syndrome Associated With CAR T Cells
November 21st 2019In an interview with Targeted Oncology, Bianca D. Santomasso, MD, PhD, discussed the challenges with treating patients who develop neurotoxicity following treatment with new CAR T cells following her talk at the 2019 SOHO Annual Meeting. She also highlighted how the CAR T cells are changing the treatment landscape for patients with lymphomas.
Read More
Emerging Data Concerning Modifiable Host Factors and Immune Responses Fuel Discussion
November 15th 2019This year’s Hot Topic Symposium during Society for Immunotherapy of Cancer’s 34th Annual Meeting, co-chaired by Jennifer A. Ligibel, MD, and Jennifer Mcquade, MD, MS, MA, focused on modifiable factors that can affect tumor response to treatment.
Read More
Clarifying Mechanisms of Resistance May Enhance Treatment Strategies
November 14th 2019Although immune checkpoint inhibitor therapy has represented a paradigm shift in the treatment of multiple types of cancer, many patients’ cancers do not respond at all to these therapies or develop resistance after an initial period of response, according to Julie R. Brahmer, MD.
Read More
SITC Handbook Addresses Multispecialty Needs to Manage Immunotherapy Toxicities
November 13th 2019The advent of immunotherapy has delivered unprecedented and durable anti-tumor responses as well as long-lasting survival benefits in some patients. Yet many clinicians may not be familiar with managing the unique toxicities that accompany these emerging cancer treatments.
Read More
Adjuvant Immunotherapy Combination Shows Activity in AXL-Positive NSCLC
November 11th 2019The combination of bemcentinib, a first in class selective AXL inhibitor, and pembrolizumab is well-tolerated in patients with composite AXL-positive non–small cell lung cancer, according to updated data presented at Society for Immunotherapy of Cancer’s 34th Annual Meeting.
Read More
TLR9 Agent Triggers Durable Response in Metastatic Melanoma
November 10th 2019The use of CMP-001, an intratumoral toll-like receptor 9 agonist, is capable of triggering durable responses when used in combination with pembrolizumab for patients with PD-1 resistant metastatic melanoma according to results from a phase Ib study presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting.
Read More
The anti–CD27 agonist, MK-5890, demonstrated acceptable safety findings when administered as monotherapy and in combination with pembrolizumab in numerous solid tumors, according to findings of an open-label phase I trial presented by Ronnie Shapira-Frommer, MD, head of the Onco-Gynecological Cancer Unit at The Ella Lemelbaum Institute for Immuno-Oncology, Ramat Gan, Israel, during the Society for Immunotherapy of Cancer’s 34<sup>th</sup> Annual Meeting.
Read More
BCMA-Directed Therapies Taking Hold in Multiple Myeloma
November 7th 2019There are at least two dozen different B-cell maturation antigen-directed therapies being explored in clinical trials, Sham Mailankody, MBBS, told attendees at the 37 Annual CFS. Mailankody, an assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, New York, highlighted the most promising anti-BCMA agents across several modalities, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.
Read More
How CAR T Cells Can Change the Treatment Landscape for Non-Hodgkin Lymphoma
November 5th 2019David Maloney, MD, PhD, medical director, Cellular Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, discusses the results of the ZUMA trial and how chimeric antigen receptor CAR T-cell therapy is changing the treatment landscape for non-Hodgkin lymphoma.
Watch
Two Novel Agents Target Emerging Molecular Alterations in Patients With Solid Tumors
November 1st 2019In solid tumors, targeted therapies are scarce for patients with mutations like KRAS or fusions like NRG1. Two clinical trials are investigating novel agents targeting these alterations to improve outcomes in patients with these particular genetic drivers of disease. The research was recently presented at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Implications of the Gut Microbiome for Cancer Immunotherapy
October 30th 2019The results of multiple studies suggest that bacteria may influence both cancer growth and the immune system, with certain species linked to improved immune surveillance of cancer. Some bacteria interact with the host’s immune system through paracrine factors to shape the immune system’s response to cancer.
Read More
Expert Predicts Immunotherapy Combos Will Transform Treatment in Multiple Myeloma
October 8th 2019<br /> In the future, we’re going to do combination therapies. They will be used in a subset of patients better defined by profiling,” Kenneth C. Anderson, MD, told an audience at the Charlotte Plasma Cell Disorder Congress in North Carolina.
Read More
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 7th 2019Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Watch